Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prucalopride vs Lubiprostone in IBS-C
NCT04985669Phase 4
Key facts
- Status
- Unknown
- Start
- Aug 2021
- Primary completion
- Feb 2022
- Countries
- 1
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Modality
- Small Molecules
- Drugs
- prucalopride
- Conditions
- irritable bowel syndrome (IBS)
01
Overview
Phase 4, open-label trial of prucalopride in irritable bowel syndrome (IBS), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Irritable Bowel Syndrome Symptom Severity Score at 6 weeks. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-label
03
Who it enrols
Adults aged 18-50 meeting Rome IV criteria for IBS-C, excluding those with organic bowel disorders, other medical causes of constipation, or abnormal laboratory results.
04
Endpoints
Primary
Irritable Bowel Syndrome Symptom Severity Score
Beyond the preview
Go deeper on NCT04985669.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985669.